Personalis (PSNL) Stock Overview
Develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PSNL Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% undervalued intrinsic discount
5419.8%Revenue growth p.a.
6.2k
18
0
126
Personalis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.78 |
| 52 Week High | US$11.50 |
| 52 Week Low | US$3.84 |
| Beta | 2.21 |
| 1 Month Change | -11.89% |
| 3 Month Change | -38.31% |
| 1 Year Change | 38.94% |
| 3 Year Change | 158.04% |
| 5 Year Change | -74.59% |
| Change since IPO | -79.71% |
Recent News & Updates
PSNL: Medicare Coverage And MRD Data Will Support Future Upside Potential
Analysts have trimmed their price target on Personalis to $10 from $11, citing updated views on longer term operating expenses and expected net losses. These updates also feed into a slightly higher discount rate and future P/E assumptions in current models.
PSNL: Higher Spending And 2026 Loss Will Set Up Longer Term Upside Potential
Analysts now converge around a $10 price target for Personalis, reflecting updated views that incorporate expectations for higher outer year operating expenses and a wider 2026 net loss. Analyst Commentary Recent research updates point to a more cautious tone around Personalis, particularly as analysts factor in guidance for higher operating expenses and a wider 2026 net loss.PSNL: Expanded Clinical Evidence And Coverage Will Support A Stronger Long Term Outlook
Analysts now center on a $10 price target for Personalis, citing updated loss expectations and higher longer term operating expense assumptions as key drivers of the shift from prior Street estimates. Analyst Commentary Bearish analysts are resetting expectations around Personalis, using the new $10 price target as a reference point for what they see as a more cautious risk and reward profile.Recent updates
PSNL: Medicare Coverage And MRD Data Will Support Future Upside Potential
Analysts have trimmed their price target on Personalis to $10 from $11, citing updated views on longer term operating expenses and expected net losses. These updates also feed into a slightly higher discount rate and future P/E assumptions in current models.PSNL: Higher Spending And 2026 Loss Will Set Up Longer Term Upside Potential
Analysts now converge around a $10 price target for Personalis, reflecting updated views that incorporate expectations for higher outer year operating expenses and a wider 2026 net loss. Analyst Commentary Recent research updates point to a more cautious tone around Personalis, particularly as analysts factor in guidance for higher operating expenses and a wider 2026 net loss.PSNL: Expanded Clinical Evidence And Coverage Will Support A Stronger Long Term Outlook
Analysts now center on a $10 price target for Personalis, citing updated loss expectations and higher longer term operating expense assumptions as key drivers of the shift from prior Street estimates. Analyst Commentary Bearish analysts are resetting expectations around Personalis, using the new $10 price target as a reference point for what they see as a more cautious risk and reward profile.
PSNL: Medicare Coverage And MRD Data Will Reprice Future Risk Reward
Analysts have adjusted their view on Personalis, with price targets now ranging between $10 and $11 as they factor in updated expectations for future losses and operating expenses. Analyst Commentary Recent research updates on Personalis highlight a mix of cautious modeling changes and ongoing interest in the company’s longer term potential.PSNL: Medicare Coverage Will Support Future Risk Reward Repricing
Narrative Update on Personalis The analyst price target on Personalis has moved from $13 to $13.00 as analysts factor in updated assumptions around revenue growth, profit margin and future P/E expectations. Analyst Commentary Bullish analysts have adjusted their price targets on Personalis, with one recent move taking the target to $13.00.PSNL: Medicare Coverage And Refined Assumptions Will Support A Brighter Outlook
Analysts have increased their price target on Personalis by $1, citing updated views on fair value, slightly revised discount rate assumptions, and refreshed expectations for revenue growth, profit margin, and future P/E. Analyst Commentary Although the latest research includes a higher price target for Personalis, the tone around the stock remains measured.PSNL: Medicare Coverage For Cancer Surveillance Will Reshape Future Risk Reward Profile
Analysts have increased their fair value estimate for Personalis from US$9.00 to US$13.00, citing updated assumptions around revenue growth, profit margins, and future P/E. They have also incorporated recent Street research that reflected Medicare coverage news and refreshed price targets.PSNL: Medicare Coverage Will Shape Future Upside Despite Biopharma Headwinds
Narrative update on Personalis Analysts have lifted their blended price expectations for Personalis toward the US$9 to US$11 range, citing recent Medicare coverage for the NeXT Personal test and Q3 revenue that came in above guidance as key supports for the higher targets. Analyst Commentary Recent Street research on Personalis has focused on two main developments: Medicare coverage for the NeXT Personal test in breast cancer surveillance, and Q3 revenue that came in ahead of the guided range, internal estimates, and consensus.Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Jan 17
PSNL: Medicare Coverage And Biopharma Headwinds Will Shape A Balanced Outlook
Analysts lifted their projected fair value for Personalis, citing recent price target increases to $9 and $11, and pointing to Medicare coverage for the NeXT Personal test and reimbursement trends as key supports for their updated view. Analyst Commentary Recent research takes a mixed view on Personalis, with price targets being adjusted around specific catalysts such as Medicare coverage for NeXT Personal and reported Q3 revenue.PSNL: Medicare Coverage Will Drive Reimbursement Momentum And Support A Higher Share Price
Analysts have raised their price target on Personalis significantly, from about $5 to a range centered near $10 per share, citing stronger revenue growth expectations, improving profit margins, and increased confidence in long-term reimbursement trends. Analyst Commentary Recent target price revisions reflect a more constructive outlook on Personalis as reimbursement visibility improves and revenue trends modestly outperform prior expectations.PSNL: Medicare Reimbursement Will Drive Future Momentum Despite Biopharma Guidance Headwinds
Analysts have modestly raised their price target on Personalis, citing stronger-than-expected Q3 revenue and expanding reimbursement visibility. Their estimate of fair value has edged up from roughly $10.71 to $11.00 per share.Personalis: A Growth Inflection Is Imminent, Hold
Nov 28PSNL: Medicare Coverage Will Support Momentum Despite Guidance Headwinds
Narrative Update on Personalis Analysts have raised their price target for Personalis from approximately $8.50 to $10.71 per share. They cite recent Medicare coverage for the NeXT Personal test and stronger-than-expected quarterly revenue as supporting factors for the upward revision.PSNL: Reimbursement Progress Will Drive Momentum Despite Guidance Reduction
Analysts have raised their fair value estimate for Personalis from $8.06 to $8.50 per share. They cite stronger revenue growth prospects and continued progress on reimbursement as key factors behind the upgrade.Personalis, Inc. (NASDAQ:PSNL) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.50
Nov 07Personalis, Inc.'s (NASDAQ:PSNL) P/S Is Still On The Mark Following 46% Share Price Bounce
Oct 31Clinical Testing Progress And Medicare Coverage Will Influence Share Momentum Ahead
Analysts have revised Personalis's price target downward from $8.00 to $6.00. They cite weaker than expected pharma order timing and softer profit projections, despite continued progress in clinical testing and Medicare coverage goals.Revenues Tell The Story For Personalis, Inc. (NASDAQ:PSNL) As Its Stock Soars 29%
Sep 16Is Personalis (NASDAQ:PSNL) A Risky Investment?
Sep 10These Analysts Think Personalis, Inc.'s (NASDAQ:PSNL) Sales Are Under Threat
Aug 10Personalis, Inc. (NASDAQ:PSNL) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
Aug 02Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 37% But Its P/S Still Looks Reasonable
May 06
NeXT Personal Testing And Moderna Partnership Will Improve Cancer Care
Strategic partnerships and agreements are expected to drive significant revenue and market expansion, particularly in MRD testing and tumor profiling.What You Can Learn From Personalis, Inc.'s (NASDAQ:PSNL) P/S After Its 40% Share Price Crash
Mar 21Personalis, Inc. (NASDAQ:PSNL) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 02Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Feb 04Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 19The Proper Play On Personalis
Oct 28Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump
Sep 14A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb
Jul 25Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower
Apr 19Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story
Mar 02Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story
Dec 18Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?
Dec 04Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely
Sep 04Shareholder Returns
| PSNL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -5.2% | -0.3% | 0.8% |
| 1Y | 38.9% | 2.2% | 27.7% |
Return vs Industry: PSNL exceeded the US Life Sciences industry which returned 5% over the past year.
Return vs Market: PSNL exceeded the US Market which returned 28.7% over the past year.
Price Volatility
| PSNL volatility | |
|---|---|
| PSNL Average Weekly Movement | 12.0% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: PSNL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PSNL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 260 | Chris Hall | www.personalis.com |
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient.
Personalis, Inc. Fundamentals Summary
| PSNL fundamental statistics | |
|---|---|
| Market cap | US$577.82m |
| Earnings (TTM) | -US$81.27m |
| Revenue (TTM) | US$69.65m |
8.7x
P/S Ratio-7.4x
P/E RatioIs PSNL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSNL income statement (TTM) | |
|---|---|
| Revenue | US$69.65m |
| Cost of Revenue | US$53.87m |
| Gross Profit | US$15.78m |
| Other Expenses | US$97.05m |
| Earnings | -US$81.27m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | -0.78 |
| Gross Margin | 22.65% |
| Net Profit Margin | -116.69% |
| Debt/Equity Ratio | 0.8% |
How did PSNL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/01 07:37 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Personalis, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| Patrick Donnelly | Citigroup Inc |